TabletsClinical Overview
Clonazepam and Desvenlafaxine Extended-Release pairs an active SNRI metabolite with a long-acting benzodiazepine. Desvenlafaxine inhibits neuronal reuptake of both serotonin and norepinephrine to reverse core neurochemical deficits in depression, while clonazepam mitigates acute agitation, panic, and sleep disturbances during therapy induction. Indicated for major depressive disorder with prominent anxiety and severe somatic distress.
Active Pharmaceutical Ingredients
Verified Clinical References
Usage Guidelines
Swallow whole with a full glass of water, with or without meals, at the same time each day. Do not crush, chew, or split extended-release tablets. Discontinue only by gradual tapering.
General Administration Advice: Adhere strictly to the prescribed dosage, frequency, and treatment course. For oral medications, swallow with sufficient water. Never stop antibiotics, psychiatric medications, or antihypertensives abruptly without clinical direction.
Possible Side Effects
Common: Nausea, somnolence, dry mouth, dizziness, insomnia, hyperhidrosis, constipation. Rare/Severe: Suicidal ideation, sustained hypertension, serotonin syndrome, angle-closure glaucoma, and dependence.
*Note: Individual physiological responses vary. While many patients experience few or no side effects, notify your treating physician if adverse reactions persist or if hypersensitivity (angioedema, skin rash, dyspnea) occurs.
Precautions & Warnings
Boxed warning for suicidality and benzodiazepine abuse/dependence. Monitor blood pressure and heart rate regularly. Contraindicated with MAOIs.
Schedule H1 (Prescription Required - Habit Forming Warning)
This medication is scheduled under statutory drug regulatory frameworks (CDSCO / Drugs & Cosmetics Rules). Dispensing requires a valid medical prescription from a registered medical practitioner. Self-medication or unsupervised dosage adjustment carries significant clinical risks.
Medical Disclaimer: Statutory Clinical Disclaimer: The information provided is for educational and price-transparency purposes only and does not constitute medical advice, clinical diagnosis, or treatment recommendations. Always consult a registered medical practitioner or qualified pharmacist before initiating, modifying, or substituting any medication regimen.
Clonazepam Tablets 0.5 mg
Clonazepam is a long-acting benzodiazepine with potent anticonvulsant, muscle-relaxant, and anxiolytic actions on the WHO Model List of Essential Medicines. It allosterically modulates GABAA receptors, increasing frequency of chloride channel opening and dampening epileptic foci in the cortex and limbic system. Indicated for panic disorder with or without agoraphobia, Lennox-Gastaut syndrome, myoclonic and akinetic seizures, and absence seizures refractory to succinimides.
Escitalopram Oxelate 10mg + Clonazepam 0.5mg Tablets
Clonazepam and Escitalopram is a premier neuropsychiatric fixed-dose combination. Escitalopram, a high-affinity SSRI, selectively inhibits presynaptic serotonin reuptake to treat core depression and panic circuitry over time, while clonazepam, a long-acting benzodiazepine, delivers immediate allosteric enhancement of GABAA receptors, dampening initial SSRI-induced jitteriness, insomnia, and acute anxiety. Indicated for major depressive disorder with comorbid anxiety, panic disorder, and generalized anxiety disorder.
Clonazepam Tablets 1mg
Clonazepam is a long-acting benzodiazepine with potent anticonvulsant, muscle-relaxant, and anxiolytic actions on the WHO Model List of Essential Medicines. It allosterically modulates GABAA receptors, increasing frequency of chloride channel opening and dampening epileptic foci in the cortex and limbic system. Indicated for panic disorder with or without agoraphobia, Lennox-Gastaut syndrome, myoclonic and akinetic seizures, and absence seizures refractory to succinimides.
Escitalopram Oxalate 5mg + Clonazepam 0.5mg Tablets
Clonazepam and Escitalopram is a premier neuropsychiatric fixed-dose combination. Escitalopram, a high-affinity SSRI, selectively inhibits presynaptic serotonin reuptake to treat core depression and panic circuitry over time, while clonazepam, a long-acting benzodiazepine, delivers immediate allosteric enhancement of GABAA receptors, dampening initial SSRI-induced jitteriness, insomnia, and acute anxiety. Indicated for major depressive disorder with comorbid anxiety, panic disorder, and generalized anxiety disorder.